October 24, interim report
July – September 2024
Alligator hosted a webinar on Thursday, October 24, at 3 p.m. CEST for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the Q3 interim report, which was followed by a Q&A session.
The call was held in English, and can be requested below.
LATEST NEWS
Alligator announces sale of future financial commitments for two bispecific antibodies to Orion Corporation
Transaction valued at €3.5 million The partners have enjoyed a successful discovery collaboration since 2021 Lund, Sweden – Allig …
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Alligator Bioscience and Aptevo Therapeutics report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, with …
Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024
The data contain efficacy results and correlative outcomes with biomarkers based on a median follow-up of 18 months in OPTIMIZE-1 trial Conf …